Overview

* Ginkgo Q3 2025 revenue falls 56% yr/yr

* Company reports Q3 GAAP net loss of $81 mln, increased from prior year

* Adjusted EBITDA for Q3 2025 declines to $(56) mln from $(20) mln last year

Outlook

* Ginkgo reaffirms 2025 total revenue of $167-$187 mln

* Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln

* Ginkgo anticipates 2025 Biosecurity revenue of at least $40 mln

Result Drivers

* REVENUE DECLINE - Q3 revenue decreased 56% yr/yr, impacted by prior year's non-cash revenue from a terminated customer agreement

* AI TECHNOLOGY - Co highlights AI-enabled cloud lab technology as a driver for U.S. scientific innovation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$80.76

Income mln

Q3 $128.85

Operatin mln

g

Expenses

Q3 -$90.02

Operatin mln

g Income

Q3 -$80.75

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc ( DNA ) is $9.00, about 28.8% below its November 5 closing price of $11.59

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)